Top Tech Companies (32)
From scientist features to #ScienceMemes and #SciComm ?Free educational videos and resources for Life Sciences? Check out our collection of free learning resources: https://info.abmgood.com/learning-resources Applied Biological Materials (abm) provides quality research reagents and custom services at incredible prices. We have an extensive product range to make abm your one-stop supplier for all your research needs: PCR, RT-PCR, qPCR, antibodies, siRNA, miRNA, CRISPR, stable...
Avivo, a British Columbia-based preclinical-stage company, has identified enzymes that convert the cell surface antigens that determine a person’s blood group to group O, the universal donor type. This innovative platform enables a world where a person’s blood type is no longer the first constraint when they need life-saving organ transplants or blood transfusions. Avivo’s platform will enable healthcare providers...
Abdera Therapeutics Inc. is a precision oncology company developing next-generation targeted radiation therapies - one of the most cutting-edge and highly promising areas of drug development. The company is built on a proprietary modular technology platform optimized for the delivery of radioisotopes to selectively destroy tumor cells while sparing healthy cells. Abdera is using this platform to enable the rapid...
Genevant is a technology-focused nucleic acid delivery company with world-class platforms, the industry’s most robust and expansive lipid nanoparticle (LNP) patent estate and decades of expertise in nucleic acid drug development. We leverage our world-class delivery systems and related technologies to bring new medicines to patients who need them. We do this by selectively collaborating with leading pharma and biotech...
Avivo, a British Columbia-based preclinical-stage company, has identified enzymes that convert the cell surface antigens that determine a person’s blood group to group O, the universal donor type. This innovative platform enables a world where a person’s blood type is no longer the first constraint when they need life-saving organ transplants or blood transfusions. Avivo’s platform will enable healthcare providers...
Genevant is a technology-focused nucleic acid delivery company with world-class platforms, the industry’s most robust and expansive lipid nanoparticle (LNP) patent estate and decades of expertise in nucleic acid drug development. We leverage our world-class delivery systems and related technologies to bring new medicines to patients who need them. We do this by selectively collaborating with leading pharma and biotech...
HTuO Biosciences is a deep tech company, working at the interface of chemistry, physics and computer programming, to develop an advanced molecular simulation capable of accurately predicting the behaviour of molecules.
Notch is an early-stage biotech company, working to maximize the benefit of cell therapies through a proprietary T cell-production platform which combines sophisticated product design with commercial-compatible processes to enhance patient outcomes. Notch’s iPSC-based technology platform allows for precision control of notch signaling, which removes several critical limiting factors in the development of cell therapies, delivering the ability to design...
Gandeeva Therapeutics is a precision biotechnology company integrating the power of cryogenic electron microscopy (cryo-EM) and machine learning to develop differentiated therapeutics by targeting and modulating key protein-protein interactions. Gandeeva’s structure-guided drug discovery platform encompasses target prediction and validation (SPOTLIGHT™), hit identification by screening virtual and fragment libraries (HYPERFOCUS™), and lead optimization (CRYO-CADD™). Gandeeva has a robust preclinical oncology pipeline...
Bold Therapeutics is the world leader in the development of novel metallotherapeutics. Bold Therapeutics' lead program, BOLD-100, has demonstrated positive safety and efficacy in Phase 2 clinical trials in colorectal, biliary tract and gastric cancers, with presentations at ASCO 2024 and ASCO GI 2024. Bold Therapeutics expects to initiate pivotal Phase 3 trials in the near future.
Acuitas is the premier LNP (lipid nanoparticle) technology provider, enabling our partners to advance new therapeutics to address unmet clinical needs. We have developed a broad IP portfolio focussed on the use of LNP technology for nucleic acid therapeutics. This portfolio primarily encompasses novel compositions of matter but also includes novel uses of nucleic acids therapeutics. Our mission is · To...
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Amgen focuses on areas of high unmet medical need and leverages its expertise to...
